RVNC Revance Therapeutics Inc.

19.91
-0.79  -4%
Previous Close 20.7
Open 20.6
Price To Book 4.05
Market Cap 736424450
Shares 36,987,667
Volume 321,405
Short Ratio
Av. Daily Volume 262,101

SEC filingsSee all SEC filings

  1. 8-K - Current report 181215428
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181157033
  3. 8-K - Current report 181153870
  4. 8-K - Current report 181117343
  5. CT ORDER - Confidential treatment order 181057562

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released January 8, 2017. Primary endpoint was not met. Further Phase 2 trial planned for 4Q 2018.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 3 commencement of dosing announced June 21, 2018.
RT002 - ASPEN
Cervical dystonia
Phase 3 data released December 5, 2017 - endpoints met. SAKURA 3 data released December 4, 2018, noted 28 week duration of effect with BLA filing due 1H 2019.
RT002 - SAKURA 1, 2 and 3
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated 2019.
RT002
Chronic migraine
Phase 2 trial to be initiated 4Q 2018.
RT002
Upper limb spasticity

Latest News

  1. Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics
  2. Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002
  3. Revance Therapeutics' Botox rival succeeds in late-stage trial
  4. Revance Announces China Market License Agreement with Fosun Pharma for RT002
  5. Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
  6. Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings
  7. Revance to Participate in Upcoming Investor Conferences
  8. Edited Transcript of RVNC earnings conference call or presentation 1-Nov-18 8:30pm GMT
  9. Why Revance Therapeutics Inc’s (NASDAQ:RVNC) CEO Pay Matters To You
  10. Revance to Participate in the Credit Suisse Healthcare Conference
  11. Revance Releases Third Quarter 2018 Results
  12. Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
  13. Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals — Discovering Underlying Factors of Influence
  14. Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
  15. Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
  16. Revance Receives Great Place to Work Certification
  17. Before You Buy Revance Therapeutics Inc’s (NASDAQ:RVNC), Consider This
  18. JMP: Changing Competitive Landscape Makes Revance Less Appealing
  19. Edited Transcript of RVNC earnings conference call or presentation 2-Aug-18 8:30pm GMT

SEC Filings

  1. 8-K - Current report 181215428
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181157033
  3. 8-K - Current report 181153870
  4. 8-K - Current report 181117343
  5. CT ORDER - Confidential treatment order 181057562
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 18992933
  7. 8-K - Current report 18988571
  8. 8-K - Current report 18914651
  9. CT ORDER - Confidential treatment order 18891756
  10. 8-K - Current report 18863098